AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15746991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg/day
Number of subjects: 50
Study 15746991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11955844 — intervention group
Group type: EXPERIMENTAL
Intervention: Double the ACE inhibitor dose (n = 10)
Number of subjects: 30
Study 11955844 — intervention group
Group type: EXPERIMENTAL
Intervention: Add an angiotensin II antagonist (n = 10)
Number of subjects: 30
Study 11955844 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n = 10)
Number of subjects: 30
Study 10206072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen for four 3‐weekly cycles
Number of subjects: 31
Study 10206072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen
Number of subjects: 31
Study 10206072 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control group (20 patients)
Number of subjects: 31
Study 7783715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive tape applied over a pectin-based barrier
Number of subjects: 20
Study 7783715 — intervention group
Group type: COMPARATOR
Intervention: Adhesive tape applied directly to the skin
Number of subjects: 20
Study 2079058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate 0.5 g.kg‐1 body mass
Number of subjects: 0
Study 7418568 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Number of subjects: 0
Study 7418568 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Number of subjects: 0
Study 7418568 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen of isoniazid (INH)
Number of subjects: 0
Study 7418568 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly regimen of rifampicin (RMP)
Number of subjects: 0
Study 31660609 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning video offered to black residents
Number of subjects: 43303
Study 31660609 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning video shown to black residents
Number of subjects: 43303
Study 31660609 — intervention group
Group type: COMPARATOR
Intervention: Cognitive impairment
Number of subjects: 43303
Study 31099866 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 2114
Study 28369299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa® enemas 25 mg/kg (up to 1g) daily for 3 weeks
Number of subjects: 38
Study 25810322 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:Glass fractional laser
Number of subjects: 40
Study 25810322 — intervention group
Group type: COMPARATOR
Intervention: Fractional radiofrequency microneedle device
Number of subjects: 40
Study 22882430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization with raw hen's egg starting from 0.27 mg (1 drop diluted 1:100) and increasing doses over 6 months
Number of subjects: 20
Study 22882430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 20
Study 20727238 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold kiwifruit with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Number of subjects: 89
Study 20727238 — intervention group
Group type: COMPARATOR
Intervention: Banana with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Number of subjects: 89
Study 19576316 — intervention group
Group type: EXPERIMENTAL
Intervention: No flow-limiting stenosis
Number of subjects: 782
Study 19576316 — intervention group
Group type: COMPARATOR
Intervention: > or =1 flow-limiting stenosis
Number of subjects: 782
Study 17968434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine with diet and exercise intervention
Number of subjects: 0
Study 17968434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0
Study 15447821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 37
Study 11447381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg, 25 mg)
Number of subjects: 60
Study 11447381 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study 9738560 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF at 5 microg/kg/d
Number of subjects: 68
Study 9738560 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotics only)
Number of subjects: 68
Study 8039407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 38000
Study 8039407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38000
Study 2975612 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg once daily
Number of subjects: 15
Study 2975612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30223903 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended GP educational programme (online and face-to-face training) with proactive discussion of pain management and prescription of paracetamol and ibuprofen according to guidelines.
Number of subjects: 250
Study 30223903 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 250
Study 27194622 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 20234
Study 27194622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20234
Study 25771087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) administered subcutaneously
Number of subjects: 69
Study 25771087 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol (Vitamin K antagonist)
Number of subjects: 69
Study 23064902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (15 g orally, three times daily)
Number of subjects: 0
Study 23064902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23064902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0
Study 21474134 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic bipolar electrocoagulation
Number of subjects: 59
Study 21474134 — intervention group
Group type: COMPARATOR
Intervention: Laparotomic hemostatic sutures
Number of subjects: 59
Study 18341663 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-photodynamic therapy (MAL-PDT)
Number of subjects: 121
Study 18341663 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 121
Study 17065974 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant selection based on drug factors (tolerability, interactions, cost), depression subtype, psychiatric and medical comorbidity, and stage of life.
Number of subjects: 0
Study 17065974 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for avoiding certain side effects and personal and family history of treatment response.
Number of subjects: 0
Study 12945061 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 35
Study 12945061 — intervention group
Group type: COMPARATOR
Intervention: Diaphragmatic Breathing (DB)
Number of subjects: 35
Study 12945061 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 35
Study 11121910 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Number of subjects: 139
Study 11121910 — intervention group
Group type: COMPARATOR
Intervention: 7-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Number of subjects: 139
Study 9085405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg daily)
Number of subjects: 26
Study 9085405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9085405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 26
Study 1350367 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of salmeterol
Number of subjects: 19
Study 1350367 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of sodium cromoglycate
Number of subjects: 19
Study 3553247 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate in optimized vehicle
Number of subjects: 40
Study 3553247 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol‐17‐propionate ointment
Number of subjects: 40
Study 3553247 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (Betamethasone and Clobetasol)
Number of subjects: 40
Study 29222596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water bath (3 °C) for 20 minutes
Number of subjects: 20
Study 29222596 — intervention group
Group type: COMPARATOR
Intervention: Neutral water bath (32 °C) for 10 minutes
Number of subjects: 20
Study 27998265 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention (workshops with leaders and selected healthcare workers)
Number of subjects: 642
Study 27998265 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 clusters, 318 healthcare workers)
Number of subjects: 642
Study 24612495 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions to improve adherence (e.g., calendar blister packs, patient education programs)
Number of subjects: 0
Study 24612495 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved adherence
Number of subjects: 0
Study 24612495 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplification of drug regimens (e.g., reducing the number of pills taken per day)
Number of subjects: 0
Study 23724808 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy)
Number of subjects: 184
Study 23724808 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel (monotherapy)
Number of subjects: 184
Study 20010312 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV at 2/3 months of age
Number of subjects: 0
Study 20010312 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV at 2/4 months of age
Number of subjects: 0
Study 20010312 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV booster responses
Number of subjects: 0
Study 20010312 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay cutoff of 0.2 microg/mL
Number of subjects: 0
Study 20010312 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of protection for serotype 6B
Number of subjects: 0
Study 18829518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg orally every month
Number of subjects: 131
Study 18829518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 19382218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (100/50 mcg twice daily)
Number of subjects: 248
Study 19382218 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (100 mcg twice daily)
Number of subjects: 248
Study 15688622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 day 1 every 4 weeks
Number of subjects: 0
Study 15688622 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m2 daily for 5 days q 21
Number of subjects: 0
Study 15688622 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD in platinum-sensitive subset
Number of subjects: 0
Study 11583862 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 44
Study 11583862 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 44
Study 11301569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 6.25 mg
Number of subjects: 175
Study 11301569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 175
Study 11301569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 175
Study 11301569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 175
Study 11301569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 8162989 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler
Number of subjects: 47
Study 8162989 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via P-MDI
Number of subjects: 47
Study 8162989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 47
Study 2463552 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate responsive pacing (minute ventilation sensing rate modulated pacemaker)
Number of subjects: 9
Study 31227460 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-assisted open reduction and internal fixation (EAORIF)
Number of subjects: 32
Study 31227460 — intervention group
Group type: COMPARATOR
Intervention: Retromandibular (RM) approach
Number of subjects: 32
Study 31227460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 32
Study 27027878 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) once daily
Number of subjects: 0
Study 27027878 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar) once daily
Number of subjects: 0
Study 26554277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-heating cigarettes
Number of subjects: 150
Study 26554277 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 150
Study 26554277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low machine yield tobacco-burning cigarettes
Number of subjects: 150
Study 24726867 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of older adults (≥65 years)
Number of subjects: 131
Study 24726867 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients with higher LASA QOL scores
Number of subjects: 131
Study 21134466 — intervention group
Group type: EXPERIMENTAL
Intervention: rHSP60
Number of subjects: 0
Study 21134466 — intervention group
Group type: EXPERIMENTAL
Intervention: rENOLASE
Number of subjects: 0
Study 21134466 — intervention group
Group type: EXPERIMENTAL
Intervention: rGAPDH
Number of subjects: 0
Study 21134466 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Ph.d.p. whole bacterial vaccine
Number of subjects: 0
Study 19552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Chemerin levels in females (109 +/- 28 microg/L)
Number of subjects: 152
Study 19552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Chemerin levels in OW/OB group (113 +/- 27 microg/L)
Number of subjects: 152
Study 19552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum Chemerin with waist circumference, WHR, fasting serum C peptide, HOMA-IR, TG, ALT, gamma-GT, uric acid
Number of subjects: 152
Study 19552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting serum C peptide and TG as independent variables of Chemerin
Number of subjects: 152
Study 17094871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 3 mg (M3 group)
Number of subjects: 45
Study 17094871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 5 mg (M5 group)
Number of subjects: 45
Study 17094871 — intervention group
Group type: COMPARATOR
Intervention: No premedication (Placebo group)
Number of subjects: 45
Study 14743850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 161
Study 14743850 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 161
Study 14743850 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (both groups)
Number of subjects: 161
Study 11236044 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 28
Study 11236044 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 28
Study 9476036 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan alone
Number of subjects: 15
Study 9476036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol alone
Number of subjects: 15
Study 9476036 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan + 1 g paracetamol
Number of subjects: 15
Study 9476036 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan + 10 mg metoclopramide
Number of subjects: 15
Study 9476036 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan + 1 g paracetamol + 10 mg metoclopramide
Number of subjects: 15
Study 3129954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 30 mg and doxapram 45 mg
Number of subjects: 24
Study 3129954 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 30 mg alone
Number of subjects: 24
Study 28320218 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cord clamping
Number of subjects: 189
Study 28320218 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 189
Study 28320218 — intervention group
Group type: COMPARATOR
Intervention: Cord milking
Number of subjects: 189
Study 27019267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (40g) with nutrition counseling
Number of subjects: 132
Study 27019267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rice flour) with nutrition counseling
Number of subjects: 132
Study 24332906 — intervention group
Group type: EXPERIMENTAL
Intervention: eFAST examination performed on-site
Number of subjects: 98
Study 24332906 — intervention group
Group type: EXPERIMENTAL
Intervention: eFAST examination performed during patient transfer
Number of subjects: 98
Study 24332906 — intervention group
Group type: EXPERIMENTAL
Intervention: eFAST examination performed in both settings
Number of subjects: 98
Study 22731641 — intervention group
Group type: EXPERIMENTAL
Intervention: eNOS Glu298Asp polymorphism genotype distribution
Number of subjects: 205
Study 22731641 — intervention group
Group type: EXPERIMENTAL
Intervention: eNOS allele frequencies
Number of subjects: 205
Study 22731641 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO levels correlation with eNOS genotype
Number of subjects: 205
Study 22731641 — intervention group
Group type: EXPERIMENTAL
Intervention: eNOS genotype distribution correlation with AMI incidence
Number of subjects: 205
Study 20850831 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (electrical stimulation)
Number of subjects: 56
Study 20850831 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 56
Study 18440756 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-EVLA (n = 23)
Number of subjects: 65
Study 18440756 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA mid-calf to groin (n = 23)
Number of subjects: 65
Study 18440756 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-EVLA + below-knee GSV foam sclerotherapy (n = 22)
Number of subjects: 65
Study 15811484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide injected subcutaneously into the arm
Number of subjects: 28
Study 15811484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide injected subcutaneously into the thigh
Number of subjects: 28
Study 15811484 — intervention group
Group type: COMPARATOR
Intervention: Exenatide injected subcutaneously into the abdomen
Number of subjects: 28
Study 11952661 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin cream applied three times daily
Number of subjects: 159
Study 11952661 — intervention group
Group type: COMPARATOR
Intervention: Oral cephalexin, 250 mg four times daily
Number of subjects: 159
Study 10217339 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg four times daily)
Number of subjects: 14
Study 10217339 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine (200 mg oral dose)
Number of subjects: 14
Study 7899419 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin (12 g/d)/tazobactam (1.5 g/d)+amikacin
Number of subjects: 222
Study 7899419 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime (3 g/d)+amikacin
Number of subjects: 222
Study 2650576 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 40
Study 2650576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 822265 — intervention group
Group type: EXPERIMENTAL
Intervention: niflumic acid (1000 mg per day)
Number of subjects: 80
Study 822265 — intervention group
Group type: COMPARATOR
Intervention: indometazin (100 mg per day)
Number of subjects: 80
Study 30058942 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy intervention (digital argument production or digital story production)
Number of subjects: 247
Study 30058942 — intervention group
Group type: COMPARATOR
Intervention: Control group (assessments only)
Number of subjects: 247
Study 27564443 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese and Lipoflavonoid Plus(®)
Number of subjects: 40
Study 27564443 — intervention group
Group type: COMPARATOR
Intervention: Lipoflavonoid Plus(®) only (Control)
Number of subjects: 40
Study 24426779 — intervention group
Group type: EXPERIMENTAL
Intervention: menatetrenone 45 mg/day
Number of subjects: 236
Study 24426779 — intervention group
Group type: COMPARATOR
Intervention: alfacalcidol 0.5 μg/day
Number of subjects: 236
Study 22341914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position with neck in neutral position
Number of subjects: 24
Study 22341914 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck flexion
Number of subjects: 24
Study 22341914 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck extension
Number of subjects: 24
Study 22341914 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 24
Study 22341914 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position
Number of subjects: 24
Study 22341914 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbent positions
Number of subjects: 24
Study 20350244 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CT (within 24 hours of admission)
Number of subjects: 118
Study 20350244 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 118
Study 20350244 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CT
Number of subjects: 118
Study 18484550 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 26
Study 18484550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26